Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1986 2
1987 2
1988 1
1989 9
1990 15
1991 20
1992 11
1993 10
1994 7
1995 12
1996 10
1997 4
1998 5
1999 6
2000 1
2001 2
2002 5
2003 8
2004 7
2005 3
2006 2
2007 5
2008 3
2009 5
2010 6
2011 9
2012 8
2013 7
2014 7
2015 7
2016 2
2017 6
2018 12
2019 5
2020 5
2021 8
2022 12
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

232 results
Results by year
Filters applied: . Clear all
Page 1
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, et al. Echt DS, et al. N Engl J Med. 1991 Mar 21;324(12):781-8. doi: 10.1056/NEJM199103213241201. N Engl J Med. 1991. PMID: 1900101 Free article. Clinical Trial.
The use of encainide and flecainide was discontinued because of excess mortality. We examined the mortality and morbidity after randomization to encainide or flecainide or their respective placebo. ...The mechanisms underlying the excess mortality …
The use of encainide and flecainide was discontinued because of excess mortality. We examined the mortality and morbidi …
Arrhythmias in Pregnancy.
Tamirisa KP, Elkayam U, Briller JE, Mason PK, Pillarisetti J, Merchant FM, Patel H, Lakkireddy DR, Russo AM, Volgman AS, Vaseghi M. Tamirisa KP, et al. JACC Clin Electrophysiol. 2022 Jan;8(1):120-135. doi: 10.1016/j.jacep.2021.10.004. Epub 2021 Dec 22. JACC Clin Electrophysiol. 2022. PMID: 35057977 Free article. Review.
Increasing maternal mortality and incidence of arrhythmias in pregnancy have been noted over the past 2 decades in the United States. ...For patients without structural heart disease, beta-blocker therapy, especially propranolol and metoprolol, and antiarrhythmic drugs, su …
Increasing maternal mortality and incidence of arrhythmias in pregnancy have been noted over the past 2 decades in the United States. …
Use of beta-blockers in atrial fibrillation.
Kühlkamp V, Bosch R, Mewis C, Seipel L. Kühlkamp V, et al. Am J Cardiovasc Drugs. 2002;2(1):37-42. doi: 10.2165/00129784-200202010-00005. Am J Cardiovasc Drugs. 2002. PMID: 14727997 Review.
There is concern that class I antiarrhythmic drugs, such as quinidine, disopyramide, and flecainide in particular, may increase mortality. The risk of proarrhythmia associated with beta-blocker treatment is very low. ...Several studies clearly show that beta-blocker …
There is concern that class I antiarrhythmic drugs, such as quinidine, disopyramide, and flecainide in particular, may increase mo …
Aconite poisoning.
Chan TY. Chan TY. Clin Toxicol (Phila). 2009 Apr;47(4):279-85. doi: 10.1080/15563650902904407. Clin Toxicol (Phila). 2009. PMID: 19514874 Review.
The main causes of death are refractory ventricular arrhythmias and asystole and the overall in-hospital mortality is 5.5%. MANAGEMENT: Management of aconite poisoning is supportive, including immediate attention to the vital functions and close monitoring of blood pressur …
The main causes of death are refractory ventricular arrhythmias and asystole and the overall in-hospital mortality is 5.5%. MANAGEMEN …
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C. Valembois L, et al. Cochrane Database Syst Rev. 2019 Sep 4;9(9):CD005049. doi: 10.1002/14651858.CD005049.pub5. Cochrane Database Syst Rev. 2019. PMID: 31483500 Free PMC article.
We found few data on mortality in people taking disopyramide, flecainide and propafenone, so it was not possible to make a reliable estimation of the mortality risk for these drugs. However, we did find moderate-certainty evidence of marked increases in proar …
We found few data on mortality in people taking disopyramide, flecainide and propafenone, so it was not possible to make a rel …
Flecainide and CAST.
[No authors listed] [No authors listed] Lancet. 1989 Aug 26;2(8661):481-2. Lancet. 1989. PMID: 2570188 Clinical Trial. No abstract available.
Flecainide: Electrophysiological properties, clinical indications, and practical aspects.
Paolini E, Stronati G, Guerra F, Capucci A. Paolini E, et al. Pharmacol Res. 2019 Oct;148:104443. doi: 10.1016/j.phrs.2019.104443. Epub 2019 Sep 4. Pharmacol Res. 2019. PMID: 31493514 Review.
While the increased mortality associated with flecainide in the Cardiac Arrhythmia Suppression Trial (CAST) still casts his shadow over flecainide clinical profile, this compound has subsequently demonstrated safe and is now used successfully for a plethora o …
While the increased mortality associated with flecainide in the Cardiac Arrhythmia Suppression Trial (CAST) still casts his sh …
Flecainide acetate for the treatment of atrial and ventricular arrhythmias.
Apostolakis S, Oeff M, Tebbe U, Fabritz L, Breithardt G, Kirchhof P. Apostolakis S, et al. Expert Opin Pharmacother. 2013 Feb;14(3):347-57. doi: 10.1517/14656566.2013.759212. Epub 2013 Jan 7. Expert Opin Pharmacother. 2013. PMID: 23294160 Review.
INTRODUCTION: Flecainide is a class Ic antiarrhythmic agent available in Europe since 1982. ...In that population, flecainide and encainide increased mortality. Consequently, sodium channel blockers are now rarely used to prevent sudden death and are not reco …
INTRODUCTION: Flecainide is a class Ic antiarrhythmic agent available in Europe since 1982. ...In that population, flecainide …
Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias.
Pritchett EL, Wilkinson WE. Pritchett EL, et al. Am J Cardiol. 1991 May 1;67(11):976-80. doi: 10.1016/0002-9149(91)90170-p. Am J Cardiol. 1991. PMID: 1902055
Mortality in the encainide population (343 patients) and the flecainide population (236 patients) was compared with that in a research arrhythmia clinic, the Duke population (154 patients). ...These descriptive comparisons did not demonstrate any excess mortality …
Mortality in the encainide population (343 patients) and the flecainide population (236 patients) was compared with that in a …
Catecholaminergic Polymorphic Ventricular Tachycardia.
Napolitano C, Mazzanti A, Bloise R, Priori SG. Napolitano C, et al. 2004 Oct 14 [updated 2022 Jun 23]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023. 2004 Oct 14 [updated 2022 Jun 23]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023. PMID: 20301466 Free Books & Documents. Review.
Flecainide can be added for primary prevention of a cardiac arrest when beta blockers alone cannot control the onset of arrhythmias during an exercise stress test. ...Evaluation of relatives at risk: Because treatment and surveillance are available to reduce morbidity and …
Flecainide can be added for primary prevention of a cardiac arrest when beta blockers alone cannot control the onset of arrhythmias d …
232 results